Terms: = Bone cancer AND TMPRSS2, PRSS10, 7113, ENSG00000184012, O15393 AND Treatment
11 results:
1. Brain metastasis in a patient with BRCA2-mutated treatment-related neuroendocrine prostate carcinoma and long-term response to radiotherapy and Olaparib: A case report and literature review.
Uehara R; Obinata D; Hashimoto S; Nakahara K; Uchida H; Yoshizawa T; Mochida J; Yamaguchi K; Sakaguchi M; Ozawa Y; Mori F; Miura K; Ishige T; Masuda S; Nakayama T; Takahashi S
Medicine (Baltimore); 2024 Mar; 103(9):e37371. PubMed ID: 38428891
[TBL] [Abstract] [Full Text] [Related]
2. Assessing survival outcomes and complication profiles following surgical excision and radiotherapy as interventions for skull base chordoma: a systematic review of operative margins and surgical approaches.
Brown NJ; Gendreau J; Kuo CC; Nguyen O; Yang C; Catapano JS; Lawton MT
J Neurooncol; 2023 Oct; 165(1):41-51. PubMed ID: 37880419
[TBL] [Abstract] [Full Text] [Related]
3. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
[TBL] [Abstract] [Full Text] [Related]
4. Novel Dormancy Mechanism of Castration Resistance in bone Metastatic Prostate cancer Organoids.
Lee S; Mendoza TR; Burner DN; Muldong MT; Wu CCN; Arreola-Villanueva C; Zuniga A; Greenburg O; Zhu WY; Murtadha J; Koutouan E; Pineda N; Pham H; Kang SG; Kim HT; Pineda G; Lennon KM; Cacalano NA; Jamieson CHM; Kane CJ; Kulidjian AA; Gaasterland T; Jamieson CAM
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328625
[TBL] [Abstract] [Full Text] [Related]
5. Prostate cancer.
Rebello RJ; Oing C; Knudsen KE; Loeb S; Johnson DC; Reiter RE; Gillessen S; Van der Kwast T; Bristow RG
Nat Rev Dis Primers; 2021 Feb; 7(1):9. PubMed ID: 33542230
[TBL] [Abstract] [Full Text] [Related]
6. tmprss2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model.
Semaan L; Mander N; Cher ML; Chinni SR
BMC Cancer; 2019 Oct; 19(1):972. PubMed ID: 31638934
[TBL] [Abstract] [Full Text] [Related]
7. bone Cell Activity in Clinical Prostate cancer bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
[TBL] [Abstract] [Full Text] [Related]
8. LuCaP Prostate cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating cancer Therapeutics.
Nguyen HM; Vessella RL; Morrissey C; Brown LG; Coleman IM; Higano CS; Mostaghel EA; Zhang X; True LD; Lam HM; Roudier M; Lange PH; Nelson PS; Corey E
Prostate; 2017 May; 77(6):654-671. PubMed ID: 28156002
[TBL] [Abstract] [Full Text] [Related]
9. Subgroups of Castration-resistant Prostate cancer bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.
Ylitalo EB; Thysell E; Jernberg E; Lundholm M; Crnalic S; Egevad L; Stattin P; Widmark A; Bergh A; Wikström P
Eur Urol; 2017 May; 71(5):776-787. PubMed ID: 27497761
[TBL] [Abstract] [Full Text] [Related]
10. A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers.
Gasi Tandefelt D; Boormans JL; van der Korput HA; Jenster GW; Trapman J
Eur Urol; 2013 Dec; 64(6):941-50. PubMed ID: 23490727
[TBL] [Abstract] [Full Text] [Related]
11. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone.
Efstathiou E; Titus M; Tsavachidou D; Tzelepi V; Wen S; Hoang A; Molina A; Chieffo N; Smith LA; Karlou M; Troncoso P; Logothetis CJ
J Clin Oncol; 2012 Feb; 30(6):637-43. PubMed ID: 22184395
[TBL] [Abstract] [Full Text] [Related]
